TY - JOUR T1 - The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic <em>Transthyretin</em> expression JF - medRxiv DO - 10.1101/2021.07.14.21260525 SP - 2021.07.14.21260525 AU - Gita A. Pathak AU - Antonella De Lillo AU - Frank R. Wendt AU - Flavio De Angelis AU - Dora Koller AU - Brenda Cabrera Mendoza AU - Daniel Jacoby AU - Edward J. Miller AU - Joel N. Buxbaum AU - Renato Polimanti Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/18/2021.07.14.21260525.abstract N2 - Background Transthyretin (TTR) is a multi-function protein involved in the systemic transport of retinol and thyroxine. It also participates in the neuronal response to stress and proteolysis of few specific substrates. TTR is also the precursor of the fibrils that compromise organ function in the familial and sporadic systemic amyloidoses (ATTR). RNA-interference and anti-sense therapeutics targeting TTR hepatic transcription have been shown to reduce TTR amyloid formation. The goal of our study was to investigate the role of genetic regulation of TTR transcriptomic variation in human traits and diseases.Methods and Findings We leveraged genetic and phenotypic information from the UK Biobank and transcriptomic profiles from the GTEx (Genotype-Tissue Expression) project to test the association of genetically regulated TTR gene expression with 7,149 traits assessed in 420,531 individuals. We conducted a joint multi-tissue analysis of TTR transcription regulation and identified an association with a specific operational procedure related to secondary open reduction of fracture of bone (p=5.46×10−6, false discovery rate q=0.039). Using tissue-specific TTR cis expression quantitative trait loci, we demonstrated that the association is driven by the genetic regulation of TTR hepatic expression (odds ratio [OR] = 3.46, 95% confidence interval [CI] = 1.85-6.44, p = 9.51×10−5). Although there is an established relationship of retinol and thyroxine abnormalities with bone loss and the risk of bone fracture, this is the first evidence of a possible effect of TTR transcriptomic regulation. Investigating the UK Biobank electronic health records available, we investigated the comorbidities affecting individuals undergoing the specific surgical procedure. Excluding medical codes related to bone fracture events, we identified a pattern of health outcomes that have been previously associated with ATTR manifestations. These included osteoarthritis (OR=3.18, 95%CI=1.93-4.25, p=9.18×10−8), carpal tunnel syndrome (OR=2.15, 95%CI=1.33-3.48, p=0.002), and a history of gastrointestinal diseases (OR=2.01, 95%CI=1.33-3.01, p=8.07×10−4).Conclusions The present study supports the notion that TTR hepatic expression can affect health outcomes linked to physiological and pathological processes presumably related to the encoded protein. Our findings highlight how the integration of omics information and electronic health records can successfully dissect the complexity of multi-function proteins such as TTR.Competing Interest StatementADL is supported by a grant from Pfizer. DJ has served as consultant and steering committee member for MyoKardia, Inc. EJM reports grants from Bracco and Eidos, and consulting for General Electric, Alnylam, and Pfizer. RP received a research grant from Pfizer. The other authors declare no conflict of interest.Funding StatementThis study was funded by a research grant from the Amyloidosis Foundation. The authors also acknowledge support from the National Institutes of Health (R21 DC018098, R33 DA047527, and F32 MH122058), the European Commission (H2020 Marie Sklodowska-Curie Individual Fellowship 101028810), and Pfizer (ATTR-PN grant 61031847). The funders had no role in the study design, data analysis, and data interpretation of the present study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Owing to the use of previously collected, deidentified data, this study did not require institutional review board approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data discussed in this study are provided in the article and in the Supplementary Material. ER -